SGLT2i and GLP-1 RA prescribing for guideline-eligible T2D patients increased 11.4% after 2019 ADA update
Prescribing SGLTis and GLP-1 RAs for Patients With Type 2 Diabetes, Guideline Updates, and Longitudinal Knowledge Assessment Scores.
Abstract
Guideline-targeted SGLT2i and GLP-1 RA prescribing for type 2 diabetes patients increased 11.4 percentage points from 2018-2022 after the 2019 ADA update.
